Page 467 - Binder2

• Has no insurance coverage for escalation—or even
for testing anti-drug antibodies?

In many countries across Sub-Saharan Africa, Southeast
Asia, Latin America, and even parts of rural North
America, biologics are used cautiously and conservatively.
If a therapy fails due to tolerization, patients may lose
their one shot at immune control.

In this landscape, durability isn’t a luxury—it’s a lifeline.

Shelf-Stable, Tolerogenic Biologics as Equalizers

Plant-based biologics, oral delivery platforms, and
immune-compatible proteins aren’t just innovations. They
are tools of health equity.

Consider what happens when a biologic:

• Requires no refrigeration.
• Is administered orally or sublingually.
• Costs a fraction of traditional protein therapies.
• Induces mucosal tolerance rather than immune
confrontation.

This is a biologic that can:

• Be grown and manufactured locally—in
decentralized greenhouses, community facilities, or
even disaster zones.
• Bypass cold chains entirely—eliminating the need
for insulated trucks, digital thermometers, and
temperature excursions.

465